Skip to content

Gastric casein coagulation and post prandial amino acid absorption: effect of the product matrix

Gastric casein coagulation and post prandial amino acid absorption: effect of the product matrix - Casco study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49160
Enrollment
15
Registered
2020-09-17
Start date
2020-12-03
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eiwitvertering bij gezonde mensen normal digestion

Interventions

The subjects will drink two 600ml dairy-based drinks containing casein and matched on macronutrient composition but differing in mineral composition.

Sponsors

Wageningen Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Male * 18 - 55 yr old * In self-reported health * BMI between 18,5 and 25kg/m2

Exclusion criteria

Exclusion criteria: * Bovine milk allergy or intolerance (self-reported) * Being vegan * Lactose intolerance (self-reported) * Disorders of the upper ingestive tract resulting in difficulties chewing/swallowing. * Unexplained weight change * Gastric disorders or regular gastric complaints, heart burn for example * Use of proton pump inhibitors or other medication which alters the normal function-ing of the stomach * Use of a medical drug use that influences the GI tract*s normal function, e.g. the motility, pH etc: among others use of proton pump inhibitors, antacids, anti-depressants etc. * Use of a medical drug use that influence the GI tract*s microbiota: antibiotic use within 1 months prior to the pre-study screenings day * Use of recreational drugs within 1 month prior to the pre-study screenings day * Alcohol consumption of more than 14 glasses/week * Smoking * Having a contra-indication to MRI scanning (including, but not limited to): * Pacemakers and defibrillators * Intraorbital or intraocular metallic fragments * Ferromagnetic implants * Claustrofobic * Not wanting information at unexpected findings

Design outcomes

Primary

MeasureTime frame
1. Postprandial plasma amino-acid concentrations 2. Gastric emptying rate

Secondary

MeasureTime frame
1. Glucose and insulin 2. Coagulation and other product instabilities if visible 3. Fullness, bloating, nausea ratings obtained after each MRI measurement

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)